Literature DB >> 11851658

Restriction enzymes in the analysis of genetic alterations responsible for cancer progression.

G J S Jenkins1, G L Williams, J Beynon, Z Ye, J N Baxter, J M Parry.   

Abstract

BACKGROUND: Molecular approaches are increasingly being employed to dissect the genetic changes accompanying tumour formation. These methods can often be confusing to the non-specialist as they include complex molecular steps. This can reduce the usefulness of such molecular data to clinicians. The authors aim to aid interpretation of molecular studies in general by presenting a comprehensive review of one molecular approach, i.e. the use of restriction enzymes in molecular studies of tumour development.
METHOD: A review was made of the molecular studies that have employed restriction enzymes in gastrointestinal cancer research. These studies have used restriction enzymes to analyse point mutation induction, gene methylation status and the deletion of chromosomal loci. In addition, emphasis is placed on some of the important considerations for the molecular analysis of tumours that can affect the molecular data obtained.
RESULTS: Restriction enzyme digestion has played, and continues to play, a major role in analysing the genetic changes in cancer. Many adaptations of basic restriction enzyme methodologies have enhanced the application of this approach in cancer genetics.
CONCLUSION: The availability of 200 different restriction enzymes, each recognizing different sequences in DNA, has been invaluable in studying cancer genetics. It is hoped that current advances in protein engineering will facilitate the creation of novel restriction enzymes with tailor-made sequence specificities. This will further improve the applicability of restriction enzymes in cancer genetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11851658     DOI: 10.1046/j.0007-1323.2001.01968.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

2.  Common patterns in type II restriction enzyme binding sites.

Authors:  Svetlana Nikolajewa; Andreas Beyer; Maik Friedel; Jens Hollunder; Thomas Wilhelm
Journal:  Nucleic Acids Res       Date:  2005-05-11       Impact factor: 16.971

Review 3.  The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA.

Authors:  Alistair Rice; Armando Del Rio Hernandez
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

4.  Evaluation of Angiotensinogen M235T and T174M Polymorphisms, Demographic and Clinical Factors in New-Onset Diabetes after Liver Transplantation in Iranian Patients.

Authors:  S Mottaghi; N Azarpira; A Dehshahri; B Khalvati; S Namazi
Journal:  Int J Organ Transplant Med       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.